{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,7]],"date-time":"2026-11-07T10:30:56Z","timestamp":1794047456532,"version":"4.8.0"},"reference-count":31,"publisher":"Ferrata Storti Foundation (Haematologica)","issue":"7","license":[{"start":{"date-parts":[[2024,1,18]],"date-time":"2024-01-18T00:00:00Z","timestamp":1705536000000},"content-version":"unspecified","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc\/4.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["haematol"],"abstract":"<jats:p>This multicenter, phase II study of the Australasian Lymphoma and Leukemia Group and the Asian Myeloma Network investigated fixed-duration (18-month) treatment with carfilzomib (K), thalidomide (T), and dexamethasone (d) (KTd) in patients with relapsed and\/or refractory multiple myeloma who had received one to three prior lines of therapy. Patients received induction with up to 12 28-day cycles of carfilzomib (20 mg\/m2 intravenously in cycle 1 on days 1 and 2, then 56 mg\/m2 [36 mg\/m2 for patients \u226575 years] from day 8 onwards), thalidomide 100 mg orally in the evening and weekly dexamethasone 40 mg (20 mg for patients \u226575 years). During maintenance, thalidomide was omitted, while carfilzomib was continued on days 1, 2, 15, and 16 with fortnightly dexamethasone. The primary endpoint was progression-free survival. Secondary endpoints were overall response rate, overall survival, duration of response, safety, and tolerability. Ninety-three patients (median age 66.3 years [range, 41.9-84.5]) were enrolled and followed up for a median of 26.4 months (range, 1.6-54.6). The median progression-free survival was 22.3 months (95% confidence interval: 15.7-25.6) and the 2-year progression-free survival was 46.3% (95% confidence interval: 35.1-52.8). The median overall survival was not reached and the 2-year overall survival was 73.8% (95% confidence interval: 62.9-81.9). The overall response rate was 88% (73% had a very good partial response or better). There was no difference in the depth of response, progression-free survival or overall survival comparing Asian and non-Asian cohorts (P=0.61). The safety profile of KTd was consistent with that of each individual drug. KTd is well tolerated and effective in patients with relapsed and\/or refractory multiple myeloma irrespective of Asian or non-Asian ethnicity and provides an alternative treatment option, particularly in circumstances in which the use of carfilzomib, lenalidomide, and dexamethasone (KRd) is limited by access, cost, or renal impairment.<\/jats:p>","DOI":"10.3324\/haematol.2023.284238","type":"journal-article","created":{"date-parts":[[2024,1,18]],"date-time":"2024-01-18T03:48:41Z","timestamp":1705549721000},"page":"2229-2238","source":"Crossref","is-referenced-by-count":1,"title":["Carfilzomib, thalidomide, and dexamethasone are safe and effective in relapsed and\/or refractory multiple myeloma: final report of the single-arm, multicenter, phase II ALLG MM018\/AMN002 study"],"prefix":"10.3324","volume":"109","author":[{"given":"Slavisa","family":"Ninkovic","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Simon J","family":"Harrison","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Je-Jung","family":"Lee","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nick","family":"Murphy","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jae Hoon","family":"Lee","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jane","family":"Estell","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Vivien M","family":"Chen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Noemi","family":"Horvath","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kihuyn","family":"Kim","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Richard","family":"Eek","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Bradley","family":"Augustson","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Soo-Mee","family":"Bang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shang-Yi","family":"Huang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rajeev","family":"Rajagopal","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ferenc","family":"Szabo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Daniel","family":"Engeler","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Belinda E","family":"Butcher","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Peter","family":"Mollee","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Brian","family":"Durie","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Wee Joo","family":"Chng","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hang","family":"Quach","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1856","published-online":{"date-parts":[[2024,1,18]]},"reference":[{"key":"63495","doi-asserted-by":"crossref","unstructured":"Kumar SK, Dispenzieri A, Lacy MQ. Continued improvement in survival in multiple myeloma: changes in early mortality and outcomes in older patients. Leukemia. 2014; 28(5):1122-1128.","DOI":"10.1038\/leu.2013.313"},{"key":"63496","doi-asserted-by":"crossref","unstructured":"Fonseca R, Abouzaid S, Bonafede M. Trends in overall survival and costs of multiple myeloma, 2000\u20132014. Leukemia. 2017; 31(9):1915-1921.","DOI":"10.1038\/leu.2016.380"},{"key":"63497","doi-asserted-by":"crossref","unstructured":"Binder M, Nandakumar B, Rajkumar SV. Mortality trends in multiple myeloma after the introduction of novel therapies in the United States. Leukemia. 2022; 36(3):801-808.","DOI":"10.1038\/s41375-021-01453-5"},{"key":"63498","doi-asserted-by":"crossref","unstructured":"Zanwar S, Nandakumar B, Kumar S. Immune-based therapies in the management of multiple myeloma. Blood Cancer J. 2020; 10(8)","DOI":"10.1038\/s41408-020-00350-x"},{"key":"63499","doi-asserted-by":"crossref","unstructured":"Mailankody S, Landgren O. T-cell engagers \u2014 modern immunebased therapies for multiple myeloma. N Engl J Med. 2022; 387(6):558-561.","DOI":"10.1056\/NEJMe2209692"},{"key":"63500","doi-asserted-by":"crossref","unstructured":"Seefat MR, Cucchi DGJ, Dirven S, Groen K, Zweegman S, Blommestein HM. A sstematic review of cost-effectiveness analyses of novel agents in the treatment of multiple myeloma. Cancers. 2021; 13(22):5606.","DOI":"10.3390\/cancers13225606"},{"key":"63501","doi-asserted-by":"crossref","unstructured":"Dimopoulos MA, Chen C, Spencer A. Long-term follow-up on overall survival from the MM-009 and MM-010 phase III trials of lenalidomide plus dexamethasone in patients with relapsed or refractory multiple myeloma. Leukemia. 2009; 23(11):2147-2152.","DOI":"10.1038\/leu.2009.147"},{"key":"63502","doi-asserted-by":"crossref","unstructured":"Musto P, Montefusco V. Are maintenance and continuous therapies indicated for every patient with multiple myeloma?. Exp Rev Hematol. 2016; 9(8):743-751.","DOI":"10.1080\/17474086.2016.1196127"},{"key":"63503","doi-asserted-by":"crossref","unstructured":"Kastritis E, Roussou M, Gavriatopoulou M. Impact of last lenalidomide dose, duration, and IMiD-free interval in patients with myeloma treated with pomalidomide\/dexamethasone. Blood Adv. 2019; 3(23):4095-4103.","DOI":"10.1182\/bloodadvances.2019000539"},{"key":"63504","doi-asserted-by":"crossref","unstructured":"Stewart AK, Rajkumar SV, Dimopoulos MA. Carfilzomib, lenalidomide, and dexamethasone for relapsed multiple myeloma. N Engl J Med. 2015; 372(2):142-152.","DOI":"10.1056\/NEJMoa1411321"},{"key":"63505","doi-asserted-by":"crossref","unstructured":"Moreau P, Masszi T, Grzasko N. Oral ixazomib, lenalidomide, and dexamethasone for multiple myeloma. N Engl J Med. 2016; 374(17):1621-1634.","DOI":"10.1056\/NEJMoa1516282"},{"key":"63506","doi-asserted-by":"crossref","unstructured":"Dimopoulos MA, Oriol A, Nahi H. Daratumumab, lenalidomide, and dexamethasone for multiple myeloma. N Engl J Med. 2016; 375(14):1319-1331.","DOI":"10.1056\/NEJMoa1607751"},{"key":"63507","doi-asserted-by":"crossref","unstructured":"Lonial S, Dimopoulos M, Palumbo A. Elotuzumab therapy for relapsed or refractory multiple myeloma. N Engl J Med. 2015; 373(7):621-631.","DOI":"10.1056\/NEJMoa1505654"},{"key":"63508","doi-asserted-by":"crossref","unstructured":"Dimopoulos MA, Moreau P, Palumbo A. Carfilzomib and dexamethasone versus bortezomib and dexamethasone for patients with relapsed or refractory multiple myeloma (ENDEAVOR): a randomised, phase 3, open-label, multicentre study. Lancet Oncol. 2016; 17(1):27-38.","DOI":"10.1016\/S1470-2045(15)00464-7"},{"key":"63509","unstructured":"Kumar S, Paiva B, Anderson KC. International Myeloma Working Group consensus criteria for response and minimal residual disease assessment in multiple myeloma. Lancet Oncol. 2016; 17(8):e328-e346."},{"key":"63510","doi-asserted-by":"crossref","unstructured":"Kropff M, Baylon HG, Hillengass J. Thalidomide versus dexamethasone for the treatment of relapsed and\/or refractory multiple myeloma: results from OPTIMUM, a randomized trial. Haematologica. 2012; 97(5):784-791.","DOI":"10.3324\/haematol.2011.044271"},{"key":"63511","doi-asserted-by":"crossref","unstructured":"Moreau P, Joshua D, Chng W-J. Impact of prior treatment on patients with relapsed multiple myeloma treated with carfilzomib and dexamethasone vs bortezomib and dexamethasone in the phase 3 ENDEAVOR study. Leukemia. 2017; 31(1):115-122.","DOI":"10.1038\/leu.2016.186"},{"key":"63512","doi-asserted-by":"crossref","unstructured":"Palumbo A, Hajek R, Delforge M. Continuous lenalidomide treatment for newly diagnosed multiple myeloma. N Engl J Med. 2012; 366(19):1759-1769.","DOI":"10.1056\/NEJMoa1112704"},{"key":"63513","doi-asserted-by":"crossref","unstructured":"Dimopoulos M, Wang M, Maisnar V. Response and progression-free survival according to planned treatment duration in patients with relapsed multiple myeloma treated with carfilzomib, lenalidomide, and dexamethasone (KRd) versus lenalidomide and dexamethasone (Rd) in the phase III ASPIRE study. J Hematol Oncol. 2018; 11(1):49.","DOI":"10.1186\/s13045-018-0583-7"},{"key":"63514","doi-asserted-by":"crossref","unstructured":"Dimopoulos MA, Stewart AK, Masszi T. Carfilzomib, lenalidomide, and dexamethasone in patients with relapsed multiple myeloma categorised by age: secondary analysis from the phase 3 ASPIRE study. Br J Haematol. 2017; 177(3):404-413.","DOI":"10.1111\/bjh.14549"},{"key":"63515","doi-asserted-by":"crossref","unstructured":"Weisel K, Mateos M-V, Gay F. Efficacy and safety profile of deep responders to carfilzomib-based therapy: a subgroup analysis from ASPIRE and ENDEAVOR. Leukemia. 2021; 35(6):1732-1744.","DOI":"10.1038\/s41375-020-01049-5"},{"key":"63516","doi-asserted-by":"crossref","unstructured":"Avet-Loiseau H, Fonseca R, Siegel D. Efficacy and safety of carfilzomib, lenalidomide, and dexamethasone vs lenalidomide and dexamethasone in patients with relapsed multiple myeloma based on cytogenetic risk status: subgroup analysis from the phase 3 atudy ASPIRE (NCT01080391). Blood. 2015; 126(23):731.","DOI":"10.1182\/blood.V126.23.731.731"},{"key":"63517","doi-asserted-by":"crossref","unstructured":"Mateos M-V, Goldschmidt H, San-Miguel J. Carfilzomib in relapsed or refractory multiple myeloma patients with early or late relapse following prior therapy: a subgroup analysis of the randomized phase 3 ASPIRE and ENDEAVOR trials. Hematol Oncol. 2018; 36(2):463-470.","DOI":"10.1002\/hon.2499"},{"key":"63518","doi-asserted-by":"crossref","unstructured":"Mellors PW, Binder M, Ketterling RP. Metaphase cytogenetics and plasma cell proliferation index for risk stratification in newly diagnosed multiple myeloma. Blood Adv. 2020; 4(10):2236-2244.","DOI":"10.1182\/bloodadvances.2019001275"},{"key":"63519","doi-asserted-by":"crossref","unstructured":"Dimopoulos M, Siegel D, White DJ. Carfilzomib vs bortezomib in patients with multiple myeloma and renal failure: a subgroup analysis of ENDEAVOR. Blood. 2019; 133(2):147-155.","DOI":"10.1182\/blood-2018-06-860015"},{"key":"63520","doi-asserted-by":"crossref","unstructured":"Quach H, White D, Spencer A. Pharmacokinetics and safety of carfilzomib in patients with relapsed multiple myeloma and end-stage renal disease (ESRD): an open-label, single-arm, phase I study. Cancer Chemother Pharmacol. 2017; 79(6):1067-1076.","DOI":"10.1007\/s00280-017-3287-8"},{"key":"63521","doi-asserted-by":"crossref","unstructured":"Iida S, Watanabe T, Matsumoto M. Carfilzomib monotherapy in Japanese patients with relapsed or refractory multiple myeloma: a phase 1\/2 study. Cancer Sci. 2019; 110(9):2924-2932.","DOI":"10.1111\/cas.14139"},{"key":"63522","doi-asserted-by":"crossref","unstructured":"Quach H, Yoon S-S, Kim K. Carfilzomib use among patients with relapsed\/refractory multiple myeloma in the Asia Pacific region: characteristics and outcomes by regimen from a prospective, real-world study. Blood. 2022; 140(Suppl 1):4264-4266.","DOI":"10.1182\/blood-2022-159324"},{"key":"63523","doi-asserted-by":"crossref","unstructured":"Dimopoulos MA, Moreau P, Iida S. Outcomes for Asian patients with multiple myeloma receiving once- or twice-weekly carfilzomib-based therapy: a subgroup analysis of the randomized phase 3 ENDEAVOR and A.R.R.O.W. trials. Int J Hematol. 2019; 110(4):466-473.","DOI":"10.1007\/s12185-019-02704-z"},{"key":"63524","doi-asserted-by":"crossref","unstructured":"Moreau P, Mateos M-V, Berenson JR. Once weekly versus twice weekly carfilzomib dosing in patients with relapsed and refractory multiple myeloma (A.R.R.O.W.): interim analysis results of a randomised, phase 3 study. Lancet Oncol. 2018; 19(7):953-964.","DOI":"10.1016\/S1470-2045(18)30354-1"},{"key":"63525","doi-asserted-by":"crossref","unstructured":"Eigbire-Molen O, Hermelin D, Blackall D. Carfilzomib-induced thrombotic microangiopathy: focus on pathogenesis. J Med Cases. 2022; 13(6):274-280.","DOI":"10.14740\/jmc3932"}],"container-title":["Haematologica"],"original-title":[],"link":[{"URL":"https:\/\/haematologica.org\/article\/download\/haematol.2023.284238\/76503","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/haematologica.org\/article\/download\/haematol.2023.284238\/77195","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/haematologica.org\/article\/download\/11411\/76503","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,11,7]],"date-time":"2026-11-07T10:05:33Z","timestamp":1794045933000},"score":1,"resource":{"primary":{"URL":"https:\/\/haematologica.org\/article\/view\/haematol.2023.284238"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,1,18]]},"references-count":31,"journal-issue":{"issue":"7","published-online":{"date-parts":[[2024,7,1]]}},"URL":"https:\/\/doi.org\/10.3324\/haematol.2023.284238","relation":{},"ISSN":["1592-8721","0390-6078"],"issn-type":[{"value":"1592-8721","type":"electronic"},{"value":"0390-6078","type":"print"}],"subject":[],"published":{"date-parts":[[2024,1,18]]}}}